Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Merck's Keytruda SC Launch Halted in Germany Amid Patent Dispute with Halozyme

Merck & Co.'s plans to introduce a subcutaneous version of its blockbuster cancer drug Keytruda in Germany have hit a significant roadblock. A German court has granted Halozyme Therapeutics a preliminary injunction, ordering Merck to cease launch activities for Keytruda SC in the country due to alleged patent infringement.

NoahAI News12/6/2025

Avalere Health Taps Sarah Hall to Lead US Marketing Amid Dynamic Political Landscape

Avalere Health, a prominent healthcare consulting firm, has announced the appointment of Sarah Hall as president of U.S. marketing. This strategic move comes at a time when the pharmaceutical industry faces increasing scrutiny and potential regulatory changes, particularly in the realm of direct-to-consumer (DTC) advertising.

NoahAI News12/6/2025

Aya Healthcare Terminates $615M Merger with Cross Country Healthcare Amid Regulatory Hurdles

Digital staffing company Aya Healthcare has announced the termination of its proposed $615 million acquisition of travel nursing company Cross Country Healthcare. The decision comes after facing significant regulatory challenges and an extended review process by the Federal Trade Commission (FTC).

NoahAI News12/6/2025

FDA Probes Takeda's Adzynma as Otsuka and Daiichi Sankyo Score Wins

The pharmaceutical industry saw significant developments this week, with regulatory actions, drug approvals, and legal battles shaping the landscape. The U.S. Food and Drug Administration (FDA) launched an investigation into Takeda's rare disease medication, while Otsuka celebrated a groundbreaking approval in the kidney disease space. Meanwhile, Daiichi Sankyo emerged victorious in a patent dispute with Pfizer's Seagen.

NoahAI News12/5/2025

Latest Developments in Alzheimer's Drug Research: Tau Targets and Beyond

Pharmaceutical companies continue to pursue innovative approaches in the fight against Alzheimer's disease, with recent clinical trial results shaping the direction of future research. While some traditional targets face setbacks, new pathways emerge, offering hope for patients and researchers alike.

NoahAI News12/5/2025

Pfizer Ventures Backs OTR Therapeutics' $100M Series A, Boosting Chinese Biotech's R&D Capabilities

Shanghai-based OTR Therapeutics has secured a substantial $100 million series A funding round, with Pfizer Ventures among the key investors. The Chinese biotech, founded in March, aims to leverage this investment to expand its research and development capabilities and advance its diverse pipeline of therapeutic candidates.

NoahAI News12/5/2025

Stryker Promotes Spencer Stiles to President and COO, Strengthening Leadership Team

Stryker, a leading medical technology company, has announced a significant change in its executive leadership. Spencer Stiles, a 27-year veteran of the company, has been promoted to the position of President and Chief Operating Officer, effective January 1, 2026. This move represents a strategic shift in Stryker's top management and signals the company's focus on leveraging internal talent for key leadership roles.

NoahAI News12/5/2025

UniQure's Huntington's Gene Therapy Faces FDA Hurdles, Casting Doubt on Approval Timeline

UniQure, a Netherlands-based biopharmaceutical company, has encountered significant regulatory challenges in its pursuit of approval for AMT-130, a potentially groundbreaking gene therapy for Huntington's disease. Recent communications with the U.S. Food and Drug Administration (FDA) have cast doubt on the therapy's path to market, leading to a sharp decline in investor confidence and the company's stock price.

NoahAI News12/5/2025

Crescent and Kelun-Biotech Forge $1.25B Partnership for Innovative Cancer Therapies

Massachusetts-based Crescent Biopharma and China's Sichuan Kelun-Biotech have announced a groundbreaking partnership worth up to $1.25 billion, focusing on the development of PD-1/VEGF bispecific antibodies and antibody-drug conjugates (ADCs) for solid tumors. This collaboration marks a significant milestone in the rapidly evolving landscape of cancer therapeutics, particularly in the realms of bispecific antibodies and ADCs.

NoahAI News12/5/2025

FDA Leadership Turmoil Continues as Vaccine Skeptic Named Acting CDER Director

The U.S. Food and Drug Administration (FDA) has appointed Tracy Beth Høeg, M.D., Ph.D., as acting director of its Center for Drug Evaluation and Research (CDER), marking the latest shake-up in agency leadership amid ongoing controversy over vaccine policies.

NoahAI News12/5/2025

Arch-Backed SciNeuro Pharmaceuticals Raises $53M for Neurodegenerative Disease Research

SciNeuro Pharmaceuticals, a biotechnology startup founded in 2020, has secured $53 million in equity financing to advance its drug development programs targeting neurodegenerative disorders. The funding round, led by Arch Venture Partners and China-based LAV, marks a significant milestone for the company as it seeks to address challenging areas of neurological drug development.

NoahAI News12/5/2025

GE HealthCare and Mayo Clinic Launch Innovative Digital Twin Project for Personalized Radiation Cancer Therapy

GE HealthCare and Mayo Clinic have announced a groundbreaking collaboration aimed at revolutionizing personalized radiation therapy for cancer patients. The initiative, named GEMINI-RT, seeks to leverage advanced imaging, artificial intelligence (AI), and patient monitoring technologies to enhance the precision and efficacy of radiation treatments.

NoahAI News12/5/2025

«1 2 3 4...67 »